Among the top stories in infectious diseases last week were reports of a beef recall prompted by a possible Salmonella outbreak and details of an invasive tick species spreading in the United States.
Other top stories included a primer for health care professionals regarding the first FDA-cleared panel that identifies sepsis-causing organisms directly from whole blood, study results that compared tests for asymptomatic malaria, and news regarding an investigational yellow fever treatment. – by Janel Miller
12 million pounds of beef recalled in multistate Salmonella outbreak
JBS Tolleson, Inc. has expanded its nationwide recall of raw beef due to possible Salmonella contamination and warned that some consumers may still have recalled meat in their freezers. Read more.
Experts ‘concerned’ about spread of Asian longhorn tick in US
Experts are concerned about the spread of an invasive tick species in the United States that is capable of transmitting a number of human infections, calling it “a new and emerging disease threat.” Read more.
T2Bacteria Panel: What you need to know
In this guest editorial, Diane C. Halstead, PhD, DABMM, FAAM, who has more than 35 years of experience as a clinical infectious disease laboratory director, discusses current data supporting T2 Biosystems’ T2Bacteria Panel, which patients should be tested using the technology, its potential economic benefits for both labs and hospitals, and how the test fits into a larger strategy to curb the use of inappropriate antibiotics. Read more.
Ultrasensitive diagnostic test for asymptomatic malaria outperforms other rapid tests
A recently developed ultrasensitive rapid diagnostic test outperformed regular rapid diagnostic tests in identifying asymptomatic malaria infections, but was still inferior to loop-mediated isothermal amplification, or LAMP, according to study findings. Read more.
Tychan announces start of clinical trial for yellow fever treatment
Tychan recently announced that its investigational treatment for yellow fever, TY014, has received regulatory approval for testing in Singapore and that the first patient in a phase 1 clinical trial has been dosed with the drug. Read more.